Timothy Bailey is an Endocrinology/Metabolic physician affiliated with AMCR Institute. ClinicalTrials.gov lists 21 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
625 Citracado Pkwy Ste 108
Escondido, CA 920256428
Telephone
760-743-1431Provider last certified this registry record 16 Apr 2021.
Clinical trials
- User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
Sponsor: Ascensia Diabetes Care
- PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
Sponsor: Dance Biopharm Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Roche Diabetes Care GmbHProgram year20256 payments$19,018openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202526 payments$12,100openpaymentsdata.cms.gov ↗
- F. Hoffmann-La Roche AGProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
64.3%l-Thyroxine44.3%Levothyroxine Sodium82%Synthroid15%Levoxyl3%Part D<11 patientsThyroid Hormone Synthesis Inhibitor10%Methimazole100%Part D≥34 patients+ 5 more classes in this area
Metabolism & gastrointestinal
17.2%Biguanide (metformin)5.6%Metformin Hcl60%Metformin Hcl Er40%Part D<11 patientsSGLT2 inhibitor4.6%Farxiga51%Jardiance49%Part D<11 patients+ 4 more classes in this area
Genitourinary & hormones
6.4%Androgen6.4%Testosterone61%Testosterone Cypionate39%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–2010 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”